Also, data published in this study indicated that tumor regression following therapeutic PD-1 blockade requires pre-existing CD8+ T cells that are negatively regulated by PD-1/PD-L1-mediated adaptive immune resistance. The gene discussed is CD8A; the disease is neoplasm.